KT-110: Innovative treatment of Addictions
Worldwide Market, First-in-Class
Tested In Phase II (PoC) clinical trial

KT-110 Timeline

General description

  • Status: Phase II completed / Phase III designed
  • Indication: Alcohol addiction
  • Targets: 5-HT2 and alpha1-adrenergic receptors, which are central in the addiction processes. Indeed, they are involved in the activation of dopamine-producing neurons and in their action on the circuit of the reward. Their simultaneous inhibition allows to oppose the addicting effects of toxicomanogenous products by avoiding the side effects such as those produced by the antipsychotics.


The goals planned for phase 2 proof of concept study were all reached:
- Confirm KT-110 safety
- Validate the pharmacological concept of recoupling reward system control
- Identify best responder population
- Determine the optimal dose
- Shape further development
Preclinical studies on other indications are pursued


KT-110 is a First in Class
innovative pharmaceutical composition

The antagonists Prazosin and Cyproheptadine entering the composition of KT-110 were strictly selected for their efficiency and on the basis of the following criteria:

  1. Regarding Prazosin, this is the gold standard among alpha-1 antagonists.
  2. Regarding Cyproheptadine, there are 3 therapeutic classes of 5-HT2 antagonists:

    • antipsychotics
    • antidepressants
    • antipsychotics
    • first generation antihistamines

In order to avoid confusion and adverse effects, antipsychotics and antidepressants were not considered. And among all first generation antihistamines, Cyprohetadine is the most used.

Synergy and IP :

  • KT-110 composition is better than other drugs such as acomposate, naltrexone or nalmefene.
  • Patented protection of the composition


  • Perfect knowledge of the components adverse effects

Preclinical trials


Selected composition:

Cyproheptadine : Antagonist of 5HT2 and 5HT1C receptors used in the treatment of allergy

Prazosin : Antagonist of alpha1-adrenergic receptors used in the treatment of arterial high blood pressure

Addiction to alcohol:

Effects of the combination on the alcohol intake and on preference to alcohol.


Cyproheptadine + Prazosin in combination (KT-110 of Kinnov Therapeutics) reverses preference to alcohol and induces a strong alcohol aversion. Other studies show better efficacy of KT-110 than available products.

Addiction to nicotine:

Effects of KT-110 on behavioral sensitization to nicotine.


Nicotine induces an hyperactivity that becomes more marked after the 2nd and 3rd injections (Behavioral Sensitization).
KT-110 antagonizes behavioral sensitization induced by nicotine

clinical trials

COCKTAIL Phase 2b study of KT-110 on alcohol addiction

Study enrolled 154 subjects in 35 french sites and showed a significant reduction in the high dose group compared to the placebo group, as well a good safety profile.

Phase 2b study on alcohol addiction was conducted for Kinnov Therapeutics by Pr. Alain Puech Selected CRO: ECSOR (www.ecsor.com), highly experienced in coordinating clinical studies in the addiction field. The clinical trial manager was Lucas Biela, who has past experience with study management in CROs, biotechs and pharmaceutical companies.

Principal investigator: Prof. Henri-Jean Aubin, Hôpital Paul Brousse, Villejuif
DSMB Pdt: Dr. Ivan Berlin, Hôpital Pitié-Salpêtrière, Paris
Both are internationally renowned for their competence in alcohol and tobacco addiction studies

list of sites available here